First Trust Advisors LP Has $11.68 Million Stake in Mednax, Inc (MD)
First Trust Advisors LP lowered its stake in shares of Mednax, Inc (NYSE:MD) by 2.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 270,842 shares of the company’s stock after selling 8,099 shares during the period. First Trust Advisors LP owned 0.29% of Mednax worth $11,679,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. BlackRock Inc. raised its stake in Mednax by 0.3% in the 2nd quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock valued at $498,505,000 after acquiring an additional 28,155 shares during the period. Vanguard Group Inc. raised its stake in Mednax by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock valued at $455,862,000 after acquiring an additional 38,645 shares during the period. Longview Partners Guernsey LTD raised its stake in Mednax by 10.3% in the 2nd quarter. Longview Partners Guernsey LTD now owns 5,023,476 shares of the company’s stock valued at $303,267,000 after acquiring an additional 467,845 shares during the period. Victory Capital Management Inc. raised its stake in Mednax by 22.6% in the 2nd quarter. Victory Capital Management Inc. now owns 2,423,865 shares of the company’s stock valued at $146,329,000 after acquiring an additional 446,074 shares during the period. Finally, Thompson Siegel & Walmsley LLC raised its stake in Mednax by 95.9% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 2,170,741 shares of the company’s stock valued at $131,048,000 after acquiring an additional 1,062,584 shares during the period. Institutional investors own 94.97% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “First Trust Advisors LP Has $11.68 Million Stake in Mednax, Inc (MD)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/10/first-trust-advisors-lp-has-11-68-million-stake-in-mednax-inc-md.html.
A number of equities research analysts recently weighed in on the company. Citigroup Inc. dropped their price target on Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. Jefferies Group LLC restated a “hold” rating and issued a $44.00 price target on shares of Mednax in a research note on Friday, November 3rd. Mizuho restated a “neutral” rating and issued a $48.00 price target (down previously from $62.00) on shares of Mednax in a research note on Tuesday, August 1st. Robert W. Baird increased their price target on Mednax from $47.00 to $48.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Finally, KeyCorp upgraded Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 price target on the stock in a research note on Sunday, September 17th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $54.50.
In other news, insider John C. Pepia sold 3,000 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the sale, the director now directly owns 44,215 shares in the company, valued at $1,883,116.85. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock.
Mednax, Inc (MD) opened at $44.65 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62. Mednax, Inc has a 1-year low of $40.56 and a 1-year high of $72.13. The company has a market capitalization of $4,164.85, a price-to-earnings ratio of 13.60, a price-to-earnings-growth ratio of 1.43 and a beta of 0.32.
Mednax (NYSE:MD) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, meeting analysts’ consensus estimates of $0.87. Mednax had a return on equity of 10.80% and a net margin of 7.76%. The firm had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. During the same period in the prior year, the firm posted $1.09 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. equities research analysts predict that Mednax, Inc will post 3.1 earnings per share for the current year.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).
Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.